Frontier Biotechnologies Inc
688221
Company Profile
Business description
Frontier Biotechnologies Inc is an innovative biomedical company. It is engaged in the production and sales of innovative drugs for major unmet clinical needs. The company focuses on the research and development of new drugs in the field of long-acting peptides and differentiated product development strategies for unmet clinical and patient needs.
Contact
No. 5 Gande Road
7th Floor, Science Park
Jiangning District, Jiangsu Province
Nanjing211122
CHNT: +86 2569648375
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
302
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 40.60 | -0.44% |
| CAC 40 | 8,108.05 | 4.21 | 0.05% |
| DAX 40 | 23,852.82 | 62.17 | 0.26% |
| Dow JONES (US) | 48,501.27 | 403.51 | -0.83% |
| FTSE 100 | 10,473.48 | 10.65 | -0.10% |
| HKSE | 25,249.48 | 518.60 | -2.01% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 54,245.54 | 2,033.51 | -3.61% |
| NZX 50 Index | 13,531.12 | 89.09 | -0.65% |
| S&P 500 | 6,816.63 | 64.99 | -0.94% |
| S&P/ASX 200 | 8,901.20 | 35.80 | -0.40% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |